Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Rybrevant Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedEmpire BluecrossPolicy CC-0201

    Rybrevant (amivantamab-vmjw), Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0201 alerts

    Get alerted when Policy CC-0201 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity and prior-authorization coverage for amivantamab-vmjw and amivantamab/hyaluronidase-lpuj in adults with specified EGFR-mutated non-small cell lung cancer, including selected brain and leptomeningeal metastases. It applies to requests reviewed under the member's medical benefit.

    Policy Summary
    PayerEmpire Bluecross
    PolicyRybrevant (amivantamab-vmjw), Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)
    Policy CodePolicy CC-0201
    Change TypeModified
    Effective DateOct 27, 2026
    Last ReviewSep 14, 2026
    Next Review DateNot scheduled
    Key ActionDocument that the requested Rybrevant or Rybrevant Faspro use satisfies a covered clinical criteria group, including diagnosis, EGFR mutation, disease status, prior therapy or progression when applicable, and the required combination regimen.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added an NCCN 2A indication for NSCLC-related leptomeningeal metastases in EGFR exon 19 deletion or exon 21 L858R substitution mutation-positive disease treated with lazertinib.

    ICD-10-CM code C79.32 for secondary malignant neoplasm of cerebral meninges was added to the coding section.

    The policy revised the coding for Rybrevant Faspro by removing HCPCS C9999 and J9999 effective June 30, 2026, and adding HCPCS J9062 effective July 1, 2026.

    2Covered drug formulations
    4FDA-approved NSCLC treatment contexts described in the overview

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    EGFR exon 19, exon 21 L858R, or exon 20 insertionRequired molecular alterations across covered indications
    2ANCCN evidence category for the added leptomeningeal-metastases indication
    4HCPCS and ICD-10 coding entries listed

    Coverage Criteria

    Initial and covered treatment pathways

    Requests may be approved when the individual is under 19 years of age or when at least one covered NSCLC indication pathway is satisfied.

    Covered request pathway

    • Age pathway: Individual is under 19 years of age.Age <19 years
    • Recurrent, advanced, or metastatic NSCLC with EGFR exon 20 insertion; single-agent therapy

      • Diagnosis: Recurrent, advanced, or metastatic NSCLC.
      • Mutation: EGFR exon 20 insertion mutations.
      • Prior treatment response: Disease progression on or after platinum-based chemotherapy.
      • No prior amivantamab progression: Individual has not progressed on prior therapy with amivantamab, any formulation.
      • Regimen: Use as a single agent.
    • First-line EGFR exon 20 insertion NSCLC

      • Diagnosis and mutation: Locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.
      • Regimen and line of therapy: First-line therapy in combination with carboplatin and pemetrexed.
    • Subsequent EGFR exon 19 or exon 21 L858R NSCLC therapy

      • Diagnosis and mutation: Recurrent, advanced, or metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R mutations.
      • Regimen and line of therapy: Subsequent therapy in combination with carboplatin and pemetrexed.
      • Prior EGFR TKI progression: Disease progression on or after treatment with an EGFR tyrosine kinase inhibitor, for example osimertinib.
    • Lazertinib combination pathway

      • Specified lazertinib treatment context

        • First line: Use as first-line therapy.
        • Continuation following disease progression on amivantamab, any formulation, and lazertinib.
        • After osimertinib: Subsequent therapy following disease progression on osimertinib for symptomatic systemic disease with multiple lesions.
        • After platinum/osimertinib/pemetrexed: Subsequent therapy if progression occurred on carboplatin or cisplatin/osimertinib/pemetrexed, if not previously given.
    • Brain metastases pathway

      • CNS diagnosis: Central nervous system cancer.
      • Primary cancer and metastasis: Primary NSCLC with disease metastasized to the brain.
      • Mutation: EGFR exon 19 deletion or exon 21 L858R substitution mutation.
      • Combination regimen

        • Lazertinib: Use in combination with lazertinib.
        • Carboplatin and pemetrexed: Use in combination with carboplatin and pemetrexed.
    • Leptomeningeal metastases pathway

      • Diagnosis: NSCLC-related leptomeningeal metastases.
      • Mutation: EGFR mutation positive for exon 19 deletion or exon 21 L858R substitution mutation.
      • Regimen: Use in combination with lazertinib.

    Indications not included in the listed coverage criteria are excluded from approval. Requests for Rybrevant or Rybrevant Faspro may not be approved when the applicable clinical criteria are not met or when the requested use is not listed in the policy.

    Coding Information

    HCPCSHCPCS
    J9061Injection, amivantamab-vmjw, 2 mg [Rybrevant]
    J9062Injection, amivantamab 5 mg and hyaluronidase-lpuj [Rybrevant Faspro]
    ICD-10 DiagnosisICD-10
    C33Malignant neoplasm of trachea
    C34.00-C34.92Malignant neoplasm of bronchus and lung
    C79.31Secondary malignant neoplasm of brain
    C79.32Secondary malignant neoplasm of cerebral meninges

    Provider Documentation and Authorization Requirements

    Documentation Required

    Clinical Criteria Required

    Clinical review, including prior authorization under the member’s medical benefit, applies to requests for Rybrevant or Rybrevant Faspro. Approval requires documentation that the member meets the applicable age, diagnosis, EGFR mutation, treatment-line, combination-regimen, and disease-progression criteria below.

    • Document the applicable diagnosis and disease setting, including NSCLC, CNS metastasis, or leptomeningeal metastases.
    • Document the EGFR mutation status: exon 20 insertion, exon 19 deletion, or exon 21 L858R substitution, as applicable.
    • Document prior therapy, disease progression, treatment line, and the requested regimen or combination.
    • Requests may also be approved when the individual is under 19 years of age.
    Step Therapy

    Prior Therapy and Progression Requirements

    For individuals 19 years of age or older, the requested use must satisfy one of the covered treatment pathways. The applicable prior-treatment, progression, mutation, and combination-therapy requirements must be documented.

    Clinical Background

    Amivantamab is a bispecific antibody directed against signaling through the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET) receptor. It is used in selected patients with EGFR-mutated non-small cell lung cancer, including certain first-line, subsequent-line, continuation, and brain or leptomeningeal metastasis treatment settings.

    Policy Definitions

    Definitions
    First-line therapyThe first or primary treatment for the diagnosis, which may include surgery, chemotherapy, radiation therapy or a combination of these therapies.
    Definitions
    Second-line therapyTreatment given when initial treatment (first-line therapy) is not effective or there is disease progression.
    Definitions
    Third-line therapyTreatment given when both initial (first-line therapy) and subsequent treatment (second-line therapy) are not effective or there is disease progression.
    Definitions

    Initial Therapy

    Initial therapy

    Initial therapy is covered when the applicable diagnosis, EGFR mutation, line of therapy, and combination requirements are satisfied.

    Initial treatment options

    • EGFR exon 20 insertion first-line combination: Individual has locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations and is receiving first-line therapy in combination with carboplatin and pemetrexed.
    • EGFR exon 19 or exon 21 L858R first-line lazertinib combination: Individual has recurrent locally advanced or metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations and is receiving first-line therapy in combination with lazertinib.

    Continuation Following Progression

    Continuation following progression

    Continuation therapy may be approved when the following covered pathway is satisfied.

    Continuation after amivantamab and lazertinib progression: Individual has recurrent locally advanced or metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations and is continuing Rybrevant or Rybrevant Faspro in combination with lazertinib following disease progression on amivantamab, any formulation, and lazertinib.

    Continuation following progression is a covered lazertinib treatment context.

    Required Treatment Sequence

    StepApplicable indicationRequired prior therapy and progressionTreatment sequence / restriction
    1EGFR exon 20 insertion-mutated recurrent, advanced, or metastatic NSCLC treated as single-agent therapyDisease progression on or after platinum-based chemotherapy; no progression on prior amivantamab in any formulationUse Rybrevant or Rybrevant Faspro as a single agent. Single-agent therapy is not covered after progression on prior amivantamab.
    1EGFR exon 19 deletion or exon 21 L858R-mutated recurrent, advanced, or metastatic NSCLC treated with carboplatin and pemetrexed as subsequent therapyDisease progression on or after treatment with an EGFR tyrosine kinase inhibitor, such as osimertinibUse in combination with carboplatin and pemetrexed as subsequent therapy.
    1EGFR exon 19 deletion or exon 21 L858R-mutated recurrent, locally advanced, or metastatic NSCLC treated with lazertinibUse the applicable prior-treatment or progression context: progression on amivantamab and lazertinib; progression on osimertinib for symptomatic systemic disease with multiple lesions; or progression on carboplatin or cisplatin, osimertinib, and pemetrexed when not previously givenUse Rybrevant or Rybrevant Faspro in combination with lazertinib in the applicable first-line, continuation, or subsequent-therapy context.
    Policy Summary
    PayerEmpire Bluecross
    PolicyRybrevant (amivantamab-vmjw), Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)
    Policy CodePolicy CC-0201
    Change TypeModified
    Effective DateOct 27, 2026
    Last ReviewSep 14, 2026
    Next Review DateNot scheduled
    Key ActionDocument that the requested Rybrevant or Rybrevant Faspro use satisfies a covered clinical criteria group, including diagnosis, EGFR mutation, disease status, prior therapy or progression when applicable, and the required combination regimen.
    SourceLink
    On This Page
    Coverage CriteriaCoding InformationProvider Documentation and Authorization RequirementsClinical BackgroundPolicy DefinitionsInitial TherapyContinuation Following ProgressionRequired Treatment Sequence
    • Single-agent pathway: Recurrent, advanced, or metastatic NSCLC with an EGFR exon 20 insertion mutation; progression on or after platinum-based chemotherapy; no progression on prior amivantamab in any formulation; and use as a single agent.
    • First-line exon 20 pathway: Locally advanced or metastatic NSCLC with an EGFR exon 20 insertion mutation, used first line in combination with carboplatin and pemetrexed.
    • Subsequent exon 19 or exon 21 pathway: Recurrent, advanced, or metastatic NSCLC with an EGFR exon 19 deletion or exon 21 L858R mutation; used with carboplatin and pemetrexed after progression on or after an EGFR tyrosine kinase inhibitor, such as osimertinib.
    • Lazertinib pathway: Recurrent locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or exon 21 L858R mutation, used with lazertinib as first-line therapy; as continuation after progression on amivantamab plus lazertinib; after progression on osimertinib for symptomatic systemic disease with multiple lesions; or after progression on carboplatin or cisplatin plus osimertinib plus pemetrexed when the regimen was not previously given.
    • CNS/brain metastasis pathway: CNS cancer with a primary NSCLC diagnosis and brain metastases, an EGFR exon 19 deletion or exon 21 L858R mutation, and use with either lazertinib or carboplatin plus pemetrexed.
    • Leptomeningeal metastasis pathway: NSCLC-related leptomeningeal metastases with an EGFR exon 19 deletion or exon 21 L858R mutation, used with lazertinib.
    Denial Risk

    Unmet Criteria or Unlisted Indication

    Requests may not be approved when the applicable criteria are not met or when the requested indication is not included in the policy. The denial restriction applies to all unlisted uses, regardless of the requested formulation.

    • Deny when the required diagnosis, EGFR mutation, treatment line, combination regimen, or prior-treatment/progression requirement is not documented.
    • Deny single-agent Rybrevant or Rybrevant Faspro when the individual has progressed on prior amivantamab in any formulation.
    • Deny requests for indications not specifically included in the covered criteria.
    • Rybrevant and Rybrevant Faspro are subject to the same listed clinical-criteria framework.
    Denial Risk

    Prior Amivantamab Progression

    Single-agent treatment is not approved after disease progression on prior amivantamab, including any formulation. This restriction applies to the single-agent pathway even when other clinical criteria are present.

    • For single-agent use, document that the individual has not progressed on prior amivantamab.
    • Continuation of amivantamab with lazertinib after progression on prior amivantamab plus lazertinib is a separate listed pathway and is not the single-agent pathway.
    MetastasisThe spread of cancer from one part of the body to another; a metastatic tumor contains cells that are like those in the original (primary) tumor and have spread.
    Definitions
    Progressive Disease (PD)Cancer that is growing, spreading, or getting worse.
    Definitions
    Refractory DiseaseIllness or disease that does not respond to treatment.
    Definitions
    Relapse or recurrenceAfter a period of improvement, during which time a disease (for example, cancer) could not be detected, the return of signs and symptoms of illness or disease. For cancer, it may come back to the same place as the original (primary) tumor or to another place in the body.